OligoNova Hub
OligoNova Hub is Sweden's new national infrastructure for drug development, focused on therapeutic oligonucleotides. Researchers with expertise in e.g. bioinformatics, chemistry and cellular biology work here with innovative development of drugs for groups of patients who currently lack appropriate treatment.
OligoNova Hub is one of four parts in a broader OligoNova organisation. In addition to the hub, there are also OligoNova Accelerate, Challenges and Network. Together, all four parts will contribute to innovative solutions, new drug patents, start-up companies and effective treatment for patients. OligoNova was initiated in 2020 by the University of Gothenburg and AstraZeneca, supported by a grant from SweLife/Vinnova.
The mission of OligoNova Hub is to support academic research with resources and expertise in the field of drug development. Our goal is to help researchers take their research results and convert them into new drugs for patient groups who currently lack appropriate treatment.
Projects Applications
In a call for projects, the HUB is currently looking for project ideas for new therapeutic oligonucleotides. The call is open for scientists with a doctoral degree at a Swedish university or higher institution.
Core Facilities
Within the Core Facilities platforms, expertise that is central to drug development projects at OligoNova Hub is already available, for example in areas like proteomics, imaging, bioinformatics, protein production and genomics. Also, the Swedish NMR Centre is located nearby at GU.
SciLifeLab DDD Platform
The Oligonova HUB focuses on a different class of drugs than those previously included in SciLifeLab's drug platform DDD. This means that new technology is added to DDD while the hub can use established expertise, instruments and existing project flows.
